Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients

被引:39
作者
Viana, Luciano de Souza [1 ,2 ,3 ]
Serufo, Jose Carlos [3 ]
da Costa Rocha, Manoel Otavio [3 ]
Costa, Renato Nogueira [1 ,2 ]
Duarte, Roberto Carlos [1 ,2 ]
机构
[1] Felicio Rocho Hosp, Dept Med Oncol, Belo Horizonte, MG, Brazil
[2] Felicio Rocho Hosp, Dept Internal Hematol, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Infectious Dis & Trop Med, Belo Horizonte, MG, Brazil
关键词
neutropenic fever; infections; fever; neutropenia;
D O I
10.1007/s00520-007-0347-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Goals of work This is a prospective and observational study comparing the efficacy of risk-assessment models in patients with neutropenic fever in a reference treatment center. The meaning of the complex infection was evaluated. Materials and methods Patients were recruited throughout a 9-month period. Inclusion criteria were histologic diagnosis of malignancy, neutropenic febrile secondary to chemotherapy and/or radiotherapy (absolute neutrophil count of < 500/mu l and axillary temperature >= 38C), and >= 18 years of age. Main results Fifty-three febrile neutropenic patients were included. Twenty one of them were classified as low risk by the Multinational Association of Supportive Care in Cancer (MASCC) risk-index score. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the MASCC risk-index scores were, respectively 87.9, 85.0, 90.6, 80.9, and 86.8%. None of the low-risk patients died, but four patients classified as low risk by the MASCC model developed serious medical complications during febrile neutropenic episodes. When we subtracted patients with complex infections from the group of patients with the MASCC risk-index score of >= 21, we got 15 patients that were classified as low risk by a proposed adjustment by complex infection (PACI) model. None of them developed serious medical complications. The sensitivity, specificity, PPV, NPV, and the accuracy of this new model were, respectively, 100, 75.0, 86.8, 100, and 90.6%. Conclusion The MASCC risk-index score had high sensitivity and specificity to predict the absence of complications, but the PACI model was better than MASCC for predicting the absence of complications in this febrile neutropenic patients.
引用
收藏
页码:841 / 846
页数:6
相关论文
共 15 条
  • [1] Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin
    Chamilos, G
    Bamias, A
    Efstathiou, E
    Zorzou, PM
    Kastritis, E
    Kostis, E
    Papadimitriou, C
    Dimopoulos, MA
    [J]. CANCER, 2005, 103 (12) : 2629 - 2635
  • [2] Cherif H, 2006, HAEMATOL-HEMATOL J, V91, P215
  • [3] DONOWITZ GR, 2001, ANN M AM SOC HEM 43
  • [4] Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials
    Elting, LS
    Rubenstein, EB
    Rolston, KVI
    Bodey, GP
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 25 (02) : 247 - 259
  • [5] Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients
    Escalante, CP
    Weiser, MA
    Manzullo, E
    Benjamin, R
    Rivera, E
    Lam, T
    Ho, V
    Valdres, R
    Lee, EL
    Badrina, N
    Fernandez, S
    DeJesus, Y
    Rolston, K
    [J]. SUPPORTIVE CARE IN CANCER, 2004, 12 (09) : 657 - 662
  • [6] 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
    Hughes, WT
    Armstrong, D
    Bodey, GP
    Bow, EJ
    Brown, AE
    Calandra, T
    Feld, R
    Pizzo, PA
    Rolston, KVI
    Shenep, JL
    Young, LS
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) : 730 - 751
  • [7] Risk assessment and treatment of low-risk patients with febrile neutropenia
    Kern, WV
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (04) : 533 - 540
  • [8] The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
    Klastersky, J
    Paesmans, M
    Rubenstein, EB
    Boyer, M
    Elting, L
    Feld, R
    Gallagher, J
    Herrstedt, J
    Rapoport, B
    Rolston, K
    Talcott, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 3038 - 3051
  • [9] Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients
    Nijhuis, CO
    Kamps, WA
    Daenen, SMG
    Gietema, JA
    van der Graaf, WTA
    Groen, HJM
    Vellenga, E
    ten Vergert, EM
    Vermeulen, KM
    de Vries-Hospers, HG
    de Bont, ESJM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7437 - 7444
  • [10] Risk factors assessment in fabrile neutropenia
    Paesmans, M
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (02) : 107 - 111